Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q8WG
|
|||
| Former ID |
DIB006506
|
|||
| Drug Name |
Tedalinab
|
|||
| Synonyms |
Tedalinab; UNII-5R7X34Y6Q1; 916591-01-0; CHEMBL3234681; 5R7X34Y6Q1; Tedalinab [INN]; SCHEMBL1431320; ZINC72266313; GRC-10693; BDBM50005917; (4S,7R)-N-tert-butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro-1H-4,7-methanoindazole-3-carboxamide; KB-80825; 4,7-Methano-1H-indazole-3-carboxamide, 1-(2,4-difluorophenyl)-N-(1,1-dimethylethyl)-4,5,6,7-tetrahydro-, (4S,7R)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 1 | [1] | |
| Company |
Glenmark Pharmaceuticals Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H21F2N3O
|
|||
| Canonical SMILES |
CC(C)(C)NC(=O)C1=NN(C2=C1C3CCC2C3)C4=C(C=C(C=C4)F)F
|
|||
| InChI |
1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1
|
|||
| InChIKey |
NTPZXHMTJGOMCJ-WDEREUQCSA-N
|
|||
| CAS Number |
CAS 916591-01-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 2 (CB2) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024918) | |||
| REF 2 | Cannabinoid CB2 receptor (CNR2). SciBX 3(46); doi:10.1038/scibx.2010.1384. Dec. 2 2010 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.